Patents Assigned to Inserm
  • RECOMBINANT VECTOR FOR PRODUCING AND SECRETING PEPTIDE OR PROTEIN OF INTEREST BY PROPIONIBACTERIA AND APPLICATIONS THEREOF
    Publication number: 20140154213
    Abstract: The present invention relates to a recombinant vector for expressing and secreting, by a propionibacterium, at least one eukaryotic peptide or protein of interest, comprising at least: under the control of at least one suitable promoter, at least one nucleic acid sequence encoding a propionibacterial signal peptide and, at least one nucleic acid sequence encoding said eukaryotic peptide or protein of interest; wherein said at least one nucleic acid sequence encoding a propionibacterial signal peptide is translationally fused to said at least one nucleic acid sequence encoding said eukaryotic peptide or protein of interest. The invention further relates to the uses of such a vector in the pharmaceutical field or for the large-scale production of peptides or proteins of interest.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 5, 2014
    Applicants: UNIVERSITE DE RENNES 1, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Gwenael JAN, Marie-Thérése DIMANCHE-BOITREL, Héléne FALENTIN, Charles HALOUZE
  • PD-1 antibodies and PD-L1 antibodies and uses thereof
    Patent number: 8741295
    Abstract: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: June 3, 2014
    Assignees: Universite de la Mediterranee, Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Daniel Olive
  • Serene protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
    Patent number: 8741286
    Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: June 3, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
  • Methods for Selecting Oocytes and Competent Embryos with High Potential for Pregnancy Outcome
    Publication number: 20140148363
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 29, 2014
    Applicant: Insitut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Samir Hamamah, John De Vos, Said Assou
  • Promyelocytic leukemia protein as a redox sensor
    Patent number: 8735171
    Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: May 27, 2014
    Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Hugues De The, Valerie Lallemand-Breitenbach
  • POLYPEPTIDES ISOLATED FROM BREVIBACTERIUM AURANTIACUM AND THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20140140978
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 22, 2014
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE PARIS SUD-PARIS XI, INRA (Institut National de la Recherche Agronomique)
    Inventors: David Machover, Pascal Bonnarme
  • ANTIBODIES AGAINST HER3
    Publication number: 20140141019
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 22, 2014
    Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • LINEAR DNA AMPLIFICATION
    Publication number: 20140141442
    Abstract: The present invention provides materials and methods for DNA amplification, in particular linear amplification methods using RNA polymerase. These methods permit high-throughput sequencing of pictogram amounts of DNA and are of use in a range of applications including genome-wide profiling of transcription factors and epigenetic DNA and histone modifications, global transcript profiling, mapping of chromatin conformations, as well as for forensic use and archaeological studies.
    Type: Application
    Filed: May 4, 2012
    Publication date: May 22, 2014
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
    Inventors: Luisa Miguel Verdelho Trindade Van Gerven, Hinrich Gronemeyer, Shankara Narayanan Pattabhiraman
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HORMONE-REFRACTORY PROSTATE CANCERS
    Publication number: 20140142168
    Abstract: The present invention relates to a combination of a curcuminoid and a taxane for use in the treatment of a hormone-refractory prostate cancer (HRPC) in a patient in need thereof.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 22, 2014
    Applicants: CENTRE JEAN PERRIN, Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE D'AUVERGNE CLERMONT
    Inventors: Chantal Barthomeuf, Philippe Chollet, Eloise Planchat, Hervé Cure
  • Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein
    Patent number: 8728727
    Abstract: The invention relates to an ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein said mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: May 20, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Hamid Azzedine, Alexis Brice, Giovanni Stevanin, Filippo Santorelli, Paola Denora
  • METHOD FOR DETECTING THE PRESENCE OF CARBAPENEMASE-PRODUCING BACTERIA IN A SAMPLE
    Publication number: 20140134656
    Abstract: The present invention relates to a method for detecting the presence of carbapenemase-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —a carbapenemase substrate selected from the group consisting of carbapenems and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of carbapenemase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of carbapenemase producers in a test sample.
    Type: Application
    Filed: June 21, 2012
    Publication date: May 15, 2014
    Applicants: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS SUD (PARIS 11)
    Inventors: Laurent Dortet, Patrice Nordmann, Laurent Poirel
  • METHODS FOR DETERMINING DEVELOPMENTAL STAGE OF HUMAN CUMULUS CELLS
    Publication number: 20140134632
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a method determining the developmental stage of human cumulus cells issues from MII oocyte.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 15, 2014
    Applicants: INSERM (Institut National de la sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventor: Samir Hamamah
  • METHODS FOR ADJUSTING EXPRESSION OF MITOCHONDRIAL GENOME BY MICRORNA
    Publication number: 20140134728
    Abstract: The present invention relates to a method for adjusting the expression of the mitochondrial genome in a human cell comprising a step consisting of modulating the expression of a least one mi RNA selected from the group consisting of hsa-mi R-1973, hsa-mi R-1275, hsa-mi R-494, hsa-mi R-513a-5p, hsa-mi R-1246, hsa-mi R-328, hsa-mi R-1908, hsa-mi R-1972, hsa-mi R-1974, hsa-mi R-1977, hsa-mi R-638, hsa-mi R-1978 and hsa-mi R-1201.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 15, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Alexandra Henrion-Caude, Simonetta Bandiera, Stanislas Lyonnet
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
    Publication number: 20140134102
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • In vitro production of a cell population using feeder cells
    Patent number: 8722401
    Abstract: A method for the in vitro production of a cell population P? from a cell population P, the production requiring the presence of at least one factor which is expressed by feeder cells, wherein a) feeder cells proliferate at a temperature T1, b) proliferated feeder cells are contacted with the cell population P, c) the cell mixture obtained at step (b) is cultivated at a temperature T2 which is chosen such that the cell population P proliferates and the feeder cells do not proliferate, the at least one factor being expressed by the feeder cells, and d) the cell population P? so produced is recovered. Advantageously, the production consists in an expansion, the feeder cells are insect feeder cells and the cell population P to be expanded is a T lymphocyte population, preferably a Trl lymphocyte population.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: May 13, 2014
    Assignees: TxCell, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Hervé Groux, Françoise Cottrez, Hervé Bastian, Valérie Brun
  • MUTANT CYTOCHROME P450 2B6 PROTEINS AND USES THEREOF
    Publication number: 20140127180
    Abstract: The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.
    Type: Application
    Filed: May 4, 2012
    Publication date: May 8, 2014
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Isabelle De Waziers, Walid Touati, Monique Diry, Jean-Pierre Flinois, Patrick Dansette, Philippe Beaune
  • Method for Expanding Monocytes
    Publication number: 20140127268
    Abstract: The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signalling.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 8, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Michael Sieweke
  • Curcuminoids in Combination Docetaxel for the Treatment of Cancer and Tumour Metastasis
    Publication number: 20140128337
    Abstract: The present invention relates to a curcuminoid for enhancing the clinical efficacy of Docetaxel for the treatment of cancers and metastases.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Chantal Barthomeuf, Philippe Chollet, Mathilde Bayet-Robert
  • Reprogrammation of eukaryotic cells with engineered microvesicles
    Patent number: 8716020
    Abstract: The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: May 6, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau, Marc Peschanski, Mathilde Girard
  • THERAPEUTIC PEPTIDES AND USE THEREOF AGAINST HUNTINGTON'S DISEASE
    Publication number: 20140121167
    Abstract: Novel therapeutic compounds for use against Huntington's disease. More especially, an isolated peptide of size less than 100 amino acids and containing: a first sequence having at least 80% identity with sequence AASSG (SEQ ID NO: 1), or a second sequence having at least 80% identity with sequence XAGXDXXTEXPXS (SEQ ID NO: 2), where X designates any amino acid. The use of an isolated peptide of size less than 200 amino acids and containing the sequence(s) defined above, as a drug is also described.
    Type: Application
    Filed: April 12, 2012
    Publication date: May 1, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS), UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Florence Maschat, Marie-Laure Parmentier, Nathalie Bonneaud, Yoan Arribat